10685652

Source:http://linkedlifedata.com/resource/pubmed/id/10685652

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0030705, umls-concept:C0038952, umls-concept:C0087111, umls-concept:C0278883, umls-concept:C0443252, umls-concept:C1519814, umls-concept:C1522405
pubmed:dateCreated	2000-3-2
pubmed:abstractText	To update response duration and survival data for patients with metastatic melanoma receiving the high-dose IV bolus recombinant interleukin (IL)-2 regimen.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/9513568
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-2, http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins
pubmed:status	MEDLINE
pubmed:month	Feb
pubmed:issn	1081-4442
pubmed:author	pubmed-author:AtkinsM BMB, pubmed-author:KunkelLL, pubmed-author:RosenbergS ASA, pubmed-author:SznolMM
pubmed:issnType	Print
pubmed:volume	6 Suppl 1
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	S11-4
pubmed:dateRevised	2006-11-15
pubmed:meshHeading	pubmed-meshheading:10685652-Follow-Up Studies, pubmed-meshheading:10685652-Humans, pubmed-meshheading:10685652-Interleukin-2, pubmed-meshheading:10685652-Melanoma, pubmed-meshheading:10685652-Recombinant Proteins, pubmed-meshheading:10685652-Survival Rate
pubmed:year	2000
pubmed:articleTitle	High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update.
pubmed:affiliation	Cytokine Working Group, Harvard University, Boston, Massachusetts, USA.
pubmed:publicationType	Journal Article, Research Support, Non-U.S. Gov't